HIV Vaccine Immunogens and Immunization Strategies
Description of Invention:
This invention relates to novel immunogens that generate an immune response against HIV-1 gp41 in mammals. The immunogens bind to the broadly neutralizing 2F5 monoclonal antibody as well as to antibodies 4E10 and Z13. The immunogens were designed based on structural considerations from peptide-2F5 complexes. These complexes were characterized and found to have specific features, necessary to elicit an antibody response. It has been difficult to elicit broadly neutralizing antibodies against HIV-1, and this technology offers a potential solution.
Inventors:
Gilad Ofek et al. (NIAID)
Patent Status:
DHHS Reference No. E-218-2004/0-US-01 -- U.S. Provisional Application No. 60/570,883 filed 14 May 2004 Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
For Additional Information Please Contact: Susan Ano Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5515
Email: anos@mail.nih.gov
Fax: (301) 402-0220
